A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)
A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)
This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.
Inclusion Criteria:
Exclusion Criteria:
Sofia, 1756, Bulgaria
Medellin-Antioquia, Colombia
Berlin, 10117, Germany
Dresden, 01307, Germany
Frankfurt, 60590, Germany
Greifswald, 17489, Germany
Hamburg, 20246, Germany
Hanover, 30625, Germany
Lübeck, 23562, Germany
Magdeburg, 39120, Germany
München, 80337, Germany
München, 80802, Germany
Münster, 48149, Germany
Quedlinburg, 06484, Germany
Würzburg, 97080, Germany
Athens, 16121, Greece
Ioannina, 455 00, Greece
Halfa, 31096, Israel
L’Aquila, Abruzzo 67100, Italy
Rome, Lazio 00167, Italy
Genoa, Liguria 16132, Italy
Milan, Lombardy 20133, Italy
Milan, Lombardy 20162, Italy
Candiolo, Piedmont 10060, Italy
Ancona, The Marches 60121, Italy
Warsaw, 00-973, Poland
Saint Petersburg, Sankt-Peterburg 197758, Russia
Palma de Mallorca, Balearic Islands 07014, Spain
Las Palmas de Gran Canaria, LAS Palmas 35020, Spain
Oviedo, Principality of Asturias 33006, Spain
Santa Cruz de Tenerife, Tenerife 38010, Spain
Toledo, 45004, Spain
New Castle Upon Tyne, NE7 7DN, United Kingdom